v3.25.2
SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Equity Offerings (Details)
6 Months Ended
May 14, 2025
USD ($)
$ / shares
shares
May 13, 2025
$ / shares
Feb. 24, 2025
USD ($)
Jun. 30, 2025
USD ($)
$ / shares
shares
Jun. 20, 2025
USD ($)
Disclosure of classes of share capital [line items]          
Proceeds from exercise of warrants $ 129,000        
Warrants issued | shares       333,333  
Warrants exercise price | $ / shares $ 1.5 $ 18.75   $ 3  
Number Of Warrants Exercised | shares 85,779        
Share issuance expenses       $ 100,000  
Risk-free interest rate | Warrants | At fair value          
Disclosure of classes of share capital [line items]          
Significant unobservable input, liabilities       0.0404  
Standard Deviation [member] | Warrants | At fair value          
Disclosure of classes of share capital [line items]          
Significant unobservable input, liabilities       1.252  
Exclusive license Agreement With Hyloris Pharmaceuticals SA [member]          
Disclosure of classes of share capital [line items]          
Upfront Payment Received     $ 100,000    
Exclusive license Agreement With Hyloris Pharmaceuticals SA [member] | Maximum          
Disclosure of classes of share capital [line items]          
Upfront Payment Receivable     $ 60,000,000    
ADS          
Disclosure of classes of share capital [line items]          
Number of shares issued | shares       890,001  
Proceeds from issuance of shares       $ 3,300,000  
Average Price Per American Depository Share | $ / shares       $ 3.85  
ADS | Alumni [member] | Maximum          
Disclosure of classes of share capital [line items]          
Maximum amount of ADS company is allowed to sell.         $ 10,000,000